A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
prohibit the importation of a drug or device that was 
manufactured at a banned foreign facility, to create in-
centives for pharmaceutical or device companies to in-
crease manufacturing capacity in the United States, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
16:09 Jun 05, 2020
H6885
2 
•HR 6885 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Safe and Secure Medi-
2
cine Supply for Hardworking Americans Act of 2020’’. 
3
SEC. 2. TABLE OF CONTENTS. 
4
The table of contents of this Act is as follows: 
5
Sec. 1. Short title. 
Sec. 2. Table of contents. 
Sec. 3. Safe drug and device importation. 
Sec. 4. Imposition of additional duties on drugs from China, India, and other 
countries. 
Sec. 5. Secure Medicines Supply Fund. 
Sec. 6. Registry of drugs manufactured outside the United States. 
Sec. 7. Country-of-origin labeling. 
SEC. 3. SAFE DRUG AND DEVICE IMPORTATION. 
6
(a) PROHIBITED ACT.—Section 301 of the Federal 
7
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
8
ed by adding at the end the following: 
9
‘‘(fff) The importation of a drug or device that was 
10
manufactured or processed at a banned foreign facility for 
11
which an order is in effect under section 810.’’. 
12
(b) ISSUANCE OF ORDER.—The Federal Food, Drug, 
13
and Cosmetic Act is amended by inserting after section 
14
809 of such Act (21 U.S.C. 384e) the following new sec-
15
tion: 
16
‘‘SEC. 810. BANNED FOREIGN FACILITIES. 
17
‘‘(a) DETERMINATION.—The Secretary shall issue an 
18
order determining a facility to be a banned foreign facility 
19
if— 
20
16:09 Jun 05, 2020
H6885
3 
•HR 6885 IH
‘‘(1) the facility manufactures or processes any 
1
drug or device that is imported into the United 
2
States; and 
3
‘‘(2) a Class I or Class II recall is issued by the 
4
Food and Drug Administration for any drug or de-
5
vice that is manufactured or processed at such facil-
6
ity. 
7
‘‘(b) DURATION.— 
8
‘‘(1) BANNED FACILITIES WITH CLASS I RE-
9
CALL.—For a banned facility for which a Class I re-
10
call is issued as described in subsection (a)(2): 
11
‘‘(A) The designation of the banned facility 
12
pursuant to an order under subsection (a), 
13
based on an initial Class I recall of a drug or 
14
device manufactured or processed at the facil-
15
ity, shall be in effect for the 10-year period be-
16
ginning on the date that is one year after the 
17
issuance of the order. 
18
‘‘(B) The designation of the banned facility 
19
pursuant to an order under subsection (a), 
20
based on a subsequent Class I recall of a drug 
21
or device manufactured or processed at the fa-
22
cility, shall be in effect permanently beginning 
23
on the date that is one year after the issuance 
24
of such order. 
25
16:09 Jun 05, 2020
H6885
4 
•HR 6885 IH
‘‘(2) BANNED FACILITIES WITH CLASS II RE-
1
CALL.—For a banned facility for which a class II re-
2
call is issued as described in subsection (a)(2): 
3
‘‘(A) The designation of the banned facility 
4
pursuant to an order under subsection (a), 
5
based on an initial Class II recall of a drug or 
6
device manufactured or processed at the facil-
7
ity, shall be in effect for the 5-year period be-
8
ginning on the date that is one year after the 
9
issuance of the order. 
10
‘‘(B) The designation of the banned facility 
11
pursuant to an order under subsection (a), 
12
based on a first subsequent Class II recall of a 
13
drug or device manufactured or processed at 
14
the facility, may be renewed to be in effect for 
15
a period of 5 years beginning— 
16
‘‘(i) if the initial 5-year period under 
17
subparagraph (A) has concluded, one year 
18
from the date of the first subsequent re-
19
call; or 
20
‘‘(ii) if the initial 5-year period under 
21
subparagraph (A) has not concluded, at 
22
the conclusion of such initial 5-year period. 
23
‘‘(C) The designation of the banned facility 
24
pursuant to an order under subsection (a), 
25
16:09 Jun 05, 2020
H6885
5 
•HR 6885 IH
based on a second subsequent Class II recall of 
1
a drug or device manufactured or processed at 
2
the facility, shall be in effect permanently be-
3
ginning— 
4
‘‘(i) if the first subsequent 5-year pe-
5
riod under subparagraph (B) has con-
6
cluded, one year after the issuance of the 
7
order; or 
8
‘‘(ii) if the first subsequent 5-year pe-
9
riod under subparagraph (B) has not con-
10
cluded, immediately. 
11
‘‘(c) DEFINITION.—In this section: 
12
‘‘(1) The term ‘banned facility’ means a banned 
13
foreign facility for which an order is in effect under 
14
subsection (a). 
15
‘‘(2) The terms ‘Class I’ and ‘Class II’, in con-
16
nection with a recall, mean classified as Class I or 
17
Class II, respectively, by the Food and Drug Admin-
18
istration pursuant to section 7.41 of title 21, Code 
19
of Federal Regulations (or any successor regula-
20
tions).’’. 
21
(c) APPLICABILITY.—Section 810 of the Federal 
22
Food, Drug, and Cosmetic Act, as added by subsection 
23
(b), applies only with respect to recalls issued or reissued 
24
on or after the date of enactment of this Act. 
25
16:09 Jun 05, 2020
H6885
6 
•HR 6885 IH
(d) CIVIL MONETARY PENALTIES.—Subsection (f) of 
1
section 303 of the Federal Food, Drug, and Cosmetic Act 
2
(21 U.S.C. 333) is amended by adding at the end the fol-
3
lowing new paragraph: 
4
‘‘(10) Any person who violates section 301(fff) shall 
5
be subject to a civil money penalty not to exceed— 
6
‘‘(A) if the violation involves a Class I recall, as 
7
described in section 810(a)(2)— 
8
‘‘(i) $25,000,000 if the violation is the first 
9
violation of section 301(fff) by such person; and 
10
‘‘(ii) $100,000,000 if the violation is a sub-
11
sequent violation of section 301(fff) by such 
12
person; and 
13
‘‘(B) if the violation involves a Class II recall, 
14
as described in section 810(a)(2)— 
15
‘‘(i) $10,000,000 if the violation is the first 
16
violation of section 301(fff) by such person; and 
17
‘‘(ii) $50,000,000 if the violation is a sub-
18
sequent violation of section 301(fff) by such 
19
person.’’. 
20
SEC. 4. IMPOSITION OF ADDITIONAL DUTIES ON DRUGS 
21
FROM CHINA, INDIA, AND OTHER COUNTRIES. 
22
(a) DRUGS FROM CHINA.— 
23
(1) IN
GENERAL.—In addition to any other 
24
duty, there is imposed a duty on drugs which are 
25
16:09 Jun 05, 2020
H6885
7 
•HR 6885 IH
being imported or offered for import into the United 
1
States (within the meaning of section 801 of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
3
381(a))) from the People’s Republic of China. 
4
(2) RATE OF DUTY.—The rate of duty imposed 
5
by paragraph (1) shall be 25 percent ad valorem. 
6
(b) DRUGS FROM INDIA.— 
7
(1) IN
GENERAL.—In addition to any other 
8
duty, there is imposed a duty on drugs which are 
9
being imported or offered for import into the United 
10
States (within the meaning of section 801 of the 
11
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
12
381(a))) from the Republic of India. 
13
(2) RATE OF DUTY.—The rate of duty imposed 
14
by paragraph (1) shall be 20 percent ad valorem. 
15
(c) DRUGS FROM OTHER COUNTRIES.— 
16
(1) IN
GENERAL.—In addition to any other 
17
duty, there is imposed a duty on drugs which are 
18
being imported or offered for import into the United 
19
States (within the meaning of section 801 of the 
20
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
21
381(a))) from any foreign country other than the 
22
People’s Republic of China or the Republic of India. 
23
(2) RATE OF DUTY.— 
24
16:09 Jun 05, 2020
H6885
8 
•HR 6885 IH
(A) IN GENERAL.—Except as provided in 
1
subparagraph (B), the rate of duty imposed by 
2
paragraph (1) shall be 10 percent ad valorem. 
3
(B) EXCEPTION.—In the case of a drug 
4
that includes one or more active pharmaceutical 
5
ingredients originating from the People’s Re-
6
public of China or the Republic of India, the 
7
rate of duty imposed by paragraph (1) shall 
8
be— 
9
(i) 25 percent ad valorem for those 
10
containing an active pharmaceutical ingre-
11
dient from China; and 
12
(ii) 20 percent ad valorem for those 
13
containing an active pharmaceutical ingre-
14
dient from India. 
15
(d) EFFECTIVE DATE.—The provisions of this sec-
16
tion shall apply to articles described in subsections (a), 
17
(b), and (c) entered, or withdrawn from warehouse for 
18
consumption, on or after the date that is 15 days after 
19
the date of the enactment of this Act. 
20
SEC. 5. SECURE MEDICINES SUPPLY FUND. 
21
(a) ESTABLISHMENT.—There is established in the 
22
Treasury of the United States a fund, to be known as the 
23
Secure Medicines Supply Fund (in this section referred 
24
to as the ‘‘Fund’’), consisting of such amounts as may 
25
16:09 Jun 05, 2020
H6885
9 
•HR 6885 IH
be deposited to the Fund pursuant to subsection (b) to 
1
be used, in accordance with subsection (c), for the purpose 
2
of supporting and incentivizing pharmaceutical or device 
3
companies to invest in new pharmaceutical or device man-
4
ufacturing capacity in the 50 States, the District of Co-
5
lumbia, Puerto Rico, the Virgin Islands, Guam, American 
6
Samoa, and the Commonwealth of the Northern Mariana 
7
Islands. 
8
(b) REQUIREMENTS.—To be eligible for investment 
9
under subsection (a), new pharmaceutical or device manu-
10
facturing capacity shall meet each of the following: 
11
(1) The products supported by the new pharma-
12
ceutical or device manufacturing capacity do not use 
13
active pharmaceutical ingredients or parts manufac-
14
tured in China or India. 
15
(2) At least 50 percent of the active pharma-
16
ceutical ingredients or parts for the total product 
17
line of the respective company is manufactured in 
18
any of the 50 States, the District of Columbia, 
19
Puerto Rico, the Virgin Islands, Guam, American 
20
Samoa, or the Commonwealth of the Northern Mar-
21
iana Islands. 
22
(c) FUNDING.— 
23
16:09 Jun 05, 2020
H6885
10 
•HR 6885 IH
(1) DUTIES.—Amounts collected from duties 
1
imposed pursuant to section 4 shall be deposited in 
2
the Fund, to remain available until expended. 
3
(2) FINES.—Amounts collected from civil mone-
4
tary penalties imposed pursuant to paragraph (10) 
5
of section 303(f) of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 333(f)), as added by sec-
7
tion 3(d), shall be deposited in the Fund, to remain 
8
available until expended. 
9
(d) DISTRIBUTION OF FUNDS.— 
10
(1) GRANTS.—The Secretary of Health and 
11
Human Services shall establish a grant program to 
12
support and incentivize pharmaceutical or device 
13
companies to manufacture prescription drugs, active 
14
pharmaceutical ingredients, or devices in any of the 
15
50 States, the District of Columbia, Puerto Rico, the 
16
Virgin Islands, Guam, American Samoa, and the 
17
Commonwealth of the Northern Mariana Islands. 
18
(2) LIMITATIONS
ON
USE
OF
FUNDS.—As a 
19
condition on receipt of a grant under this section, 
20
the recipient of the grant shall agree to use— 
21
(A) not more than 10 percent of the grant 
22
for new or expanded manufacturing capacity; 
23
(B) not more than 50 percent of the grant 
24
for training manufacturing workers; and 
25
16:09 Jun 05, 2020
H6885
11 
•HR 6885 IH
(C) not more than 25 percent of the grant 
1
for developing one or more new prescription 
2
drugs, new active pharmaceutical ingredients, 
3
or new antibiotics. 
4
(3) SOURCE OF FUNDING.—All amounts used 
5
to carry out this section shall be derived from the 
6
Fund. 
7
(e) REPORT.—Not later than one year after the date 
8
of enactment of this Act, and annually thereafter, the Sec-
9
retary of Health and Human Services shall submit to the 
10
Congress a report on the Fund. Each such report shall 
11
address the following: 
12
(1) The amounts deposited into the Fund in the 
13
most recent three fiscal years. 
14
(2) The distribution of such amounts pursuant 
15
to grants under this section during the last three fis-
16
cal years, including the allocation of such amounts 
17
for— 
18
(A) new or expanded manufacturing capac-
19
ity; 
20
(B) training workers; and 
21
(C) developing new prescription drugs, new 
22
active pharmaceutical ingredients, or new anti-
23
biotics. 
24
16:09 Jun 05, 2020
H6885
12 
•HR 6885 IH
(f) DEVICE.—In this section, the term ‘‘device’’ has 
1
the meaning given to such term in section 201 of the Fed-
2
eral Food, Drug, and Cosmetic Act (21 U.S.C. 321). 
3
(g) SUNSET.—This section (other than subsection 
4
(e)) shall cease to have effect beginning on the date that 
5
is 10 years after the date of the enactment of this Act. 
6
(h) UNUSED FUNDS RETURNED TO THE GENERAL 
7
FUND OF THE TREASURY.—If any amounts remain in the 
8
Fund after the date described in subsection (f), the Sec-
9
retary of the Treasury shall transfer such amounts to the 
10
general fund of the Treasury. 
11
SEC. 6. REGISTRY OF DRUGS MANUFACTURED OUTSIDE 
12
THE UNITED STATES. 
13
The Federal Food, Drug, and Cosmetic Act is amend-
14
ed by inserting after section 524A of such Act (21 U.S.C. 
15
360n–1) the following new section: 
16
‘‘SEC. 524B. REGISTRY OF DRUGS MANUFACTURED OUT-
17
SIDE THE UNITED STATES. 
18
‘‘(a) IN GENERAL.—The Secretary shall compile and 
19
maintain a registry of all drugs approved under subsection 
20
(c) or (j) of section 505 of this Act or licensed under sub- 
21
section (a) or (k) of section 351 of the Public Health Serv-
22
ice Act, and any active pharmaceutical ingredients in such 
23
drugs, that are manufactured outside of the United 
24
16:09 Jun 05, 2020
H6885
13 
•HR 6885 IH
States. The Secretary shall update such registry at least 
1
biannually. 
2
‘‘(b) ADDITIONAL LIST.— 
3
‘‘(1) IN
GENERAL.—In conjunction with the 
4
registry under subsection (a), the Secretary shall 
5
compile and maintain a list of those drugs included 
6
in the registry for which 50 percent or more of their 
7
active pharmaceutical ingredients are manufactured 
8
in locations within a single country outside the 
9
United States. 
10
‘‘(2) CONTENTS.—The list of drugs under para-
11
graph (1) shall— 
12
‘‘(A) identify both the drugs and the asso-
13
ciated sole-source country; 
14
‘‘(B) be updated at least bi-annually; and 
15
‘‘(C) be publicly available. 
16
‘‘(c) REQUIREMENT.—The registry under subsection 
17
(a) shall, with respect to each drug included on the reg-
18
istry, provide information about the drug’s supply chain, 
19
including each step in the supply chain that occurs prior 
20
to the drug’s importation into the United States.’’. 
21
SEC. 7. COUNTRY-OF-ORIGIN LABELING. 
22
Section 502 of the Federal Food, Drug, and Cosmetic 
23
Act (21 U.S.C. 352) is amended by adding at the end the 
24
following: 
25
16:09 Jun 05, 2020
H6885
14 
•HR 6885 IH
‘‘(ee) If it is a drug and its labeling does not specify 
1
the country of origin of each active pharmaceutical ingre-
2
dient contained in the drug.’’. 
3
Æ 
16:09 Jun 05, 2020
H6885
